Earnings Call: 23andMe Reports Decreased Revenue, Narrows Losses

InvestingAug 9 17:58 ET

Earnings Call Summary | 23andMe(ME.US) Q1 2025 Earnings Conference

moomoo AIAug 9 17:54 ET · Conference Call

23andMe Shuts Down Therapeutics Discovery Unit, Launching GLP-1 Telehealth Offering

Seeking AlphaAug 9 17:01 ET

23andMe Holding Co. (ME) Q1 2025 Earnings Call Transcript

Earnings Call TranscriptsAug 9 15:58 ET

Former Wall Street darling 23andMe is in trouble and is entering the weight loss drug market with all its might.

According to a press release published on Thursday, the company plans to launch a weight-loss membership program on its telemedicine platform Lemonaid by the end of this month. Users will be able to obtain brand-name drugs or combination preparations of semaglutide, the active ingredient in the Novo Nordisk blockbuster weight-loss drug, on the platform. 23andMe also plans to launch a new genetic study focusing on popular diabetes and weight-loss drugs to identify gene variants associated with weight loss and side effects.

wallstreetcnAug 8 18:31 ET

Express News | 23Andme Holding Co. Qtrly Shr Loss $0.14

ReutersAug 8 17:12 ET